- Supported exchanges /
- F /
- C4X.F
Onxeo SA (C4X F) stock market data APIs
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes. The company develops AsiDNA, which is in Phase 1b/2 trial in combination with the PARP inhibitor Olaparib to evaluate safety in patients with epithelial ovarian cancer, breast cancer, and metastatic castration-resistant prostate cancer. It also develops Revocan that is in Phase 1b/2 trial to evaluate the addition of AsiDNA to combat PARP inhibitor resistance in second-line maintenance treatment of recurrent ovarian cancer, as well as in phase 1b/2 trial evaluating AsiDNA in combination with radiotherapy in recurrent highgrade glioma in children. In addition, it is developing VIO-01, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; and PlatON, a chemistry platform for building new molecules, which include OX400, a decoy DNA platform. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. The company was founded in 1997 and is headquartered in Paris, France.
Onxeo SA Financial Data Overview
| 0.0804 | |
| 0.072 | |
| - | |
| 0.0804 | |
| 0.072 | |
| 0.0661-0.196 | |
| 12 516 K | |
| 154 M | |
| 1 889 K | |
| 1.658 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Onxeo SA Fundamental Data is available in our Financial Data APIs
- Net Revenue 1 889 K
- EBITDA -16 455 000
- Earnings Per Share -0.14
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Onxeo SA Earnings via APIs
- Latest Release 2024-10-03
- EPS/Forecast NaN
Get Onxeo SA End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
